Women are exposed to estrogen and/or progestogen through several means such as hormonal contraceptives and hormone replacement therapies. The cardiometabolic effects of using oral contraceptive (OC) in particular are still inconclusive (1). High C-reactive protein (C-RP), uric acid (UA) as well as triglycerides (TG)/high-density lipoprotein cholesterol (HDL-C) ratio are now widely accepted as salient atherosclerotic risk indicators, independently predicting future cardiovascular events (2-4). The present study therefore sought to determine the effects of combined OC steroids on C-RP, UA and TG/HDL-C ratio in a female rat model with impaired glucose tolerance. Twelve female Wistar rats weighing between 120 and 180g were randomly allotted to OC-treated (n=6) and vehicle-treated (n=6) groups. OC-treated rats received a combination of OC steroids (15.0 μg norgestrel and 1.5 μg ethinyl estradiol/rat; NEE, p.o.) while vehicle-treated rats were given distilled water (0.3ml/rat, p.o.) daily for 6 weeks. Rats had unrestricted access to food and water. An oral glucose tolerance test was performed after 12-hour overnight fast, and glucose tolerance was expressed as a function of the area under the tolerance curve (AUC). Values are means ± S.E.M., compared by independent t-test. When compared with the vehicle-treated rats, OC treatment led to significant decreases in glucose tolerance (AUC: 288.8±12.5 vs. 398.5.4±10.2mg/dl, p<0.05), circulating 17β-oestradiol (13.1±0.2 vs. 4.8±0.8pg/ml, p<0.05) and testosterone (0.38±0.02 vs. 0.11±0.03ng/ml p<0.05). On the other hand, there were significant increases in plasma UA (181.6±11.2 vs. 483.0±14.9µmol/L, p<0.05), TG (89.2±7.3 vs. 156.1±11.2mg/dl, p<0.05), TG/HDL-C ratio (1.8±0.2 vs. 3.2±0.1, p<0.05) with OC treatment. However, fasting blood glucose, plasma total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), HDL-C, TC/HDL-C ratio, C-RP, total protein and albumin levels were not significantly affected by OC treatment. These results demonstrate that OC-induced impaired glucose tolerance is associated with high plasma UA and TG/HDL-C ratio, but not with increased plasma C-RP level. The findings imply that dyslipidemia associated with OC-induced impaired glucose tolerance may promote atherosclerotic complications, and that plasma level of UA but not that of C-RP may be an important factor to be monitored during OC use.